Cabotegravir Injection [Apretude]
Cabotegravir Injection [Apretude] is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
3
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa
Clinical Trials (4)
Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4